News

Eli Lilly's Mounjaro Outperforms Trulicity in Latest Study

Eli Lilly's Mounjaro Outperforms Trulicity in Latest Study

Eli Lilly's Mounjaro Shines in Recent Clinical Trial

Eli Lilly and Co. has made headlines with the recent release of impressive topline results from the SURPASS-CVOT trial, a significant Phase 3 study evaluating cardiovascular outcomes. The trial compares Mounjaro, a GIP/GLP-1 dual receptor agonist, with Trulicity, which is a recognized GLP-1 receptor agonist.

Significant Outcomes for Mounjaro

During the SURPASS-CVOT trial, Mounjaro met its primary endpoint by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3). This includes critical conditions such as cardiovascular death, heart attack, and stroke when compared to Trulicity.

Key Highlights of the Trial

Interestingly, while statistical considerations for multiple endpoints were not strictly adhered to, Mounjaro showed substantial improvements in several key health metrics. These included reductions in A1C levels, weight loss, enhanced renal function, and a lower rate of all-cause mortality.

Trial Details and Enrollment

The carefully designed trial enrolled over 13,000 participants, making it the largest and longest study of tirzepatide, the active ingredient in Mounjaro. This comprehensive exploration lasted over four years, offering a robust dataset to draw conclusions from.

Comparative Benefits

Mounjaro outperformed Trulicity in reducing the likelihood of cardiovascular-related deaths, heart attacks, or strokes by an impressive 8%. This result affirms the non-inferiority of Mounjaro to its predecessor.

Healthcare Impact

Mounjaro showed promising results across all components outlined in the MACE-3 composite. Furthermore, there was a notable 16% decrease in the overall mortality rate associated with Mounjaro versus Trulicity. In an indirect comparison analysis using patient-level data, Mounjaro reduced MACE-3 incidents by 28% and all-cause mortality by 39% compared to a theoretical placebo.

Previous Studies and Relevant Comparisons

The REWIND study, published in 2019, documented definitive cardiovascular benefits linked to Trulicity. This study served as a multicenter, randomized, double-blind, placebo-controlled investigation into how Trulicity affects participants with type 2 diabetes, encompassing both those with established cardiovascular disease and those without.

Following trends in the industry, Mounjaro looks to build on this knowledge. The recent data further positions it as a leading contender in the management of obesity and associated cardiovascular risks.

Summary of Efficacy

For patients at heightened risk of chronic kidney disease, Mounjaro was effective in slowing the decline of the estimated glomerular filtration rate by 3.54 mL/min/1.73 m2 after 36 months compared to Trulicity.

Conclusion and Future Plans

Moreover, Mounjaro displayed superior outcomes concerning weight, A1C levels, and cardiovascular biomarkers, leading to enhancements in lipids and systolic blood pressure. It's worth noting that safety and tolerability profiles for both Mounjaro and Trulicity remained consistent with established expectations across the patient groups.

Market Implications

With 13.3% of participants on Mounjaro discontinuing treatment due to adverse effects compared to 10.2% for those on Trulicity, Eli Lilly is planning to share these vital data with global regulatory authorities by the year's end.

In a related observation, two years ago, Novo Nordisk A/S’s SELECT cardiovascular outcomes trial revealed a statistically significant 20% reduction in MACE with semaglutide treatment—an important benchmark within the obesity treatment landscape. Currently, stocks for LLY are down marginally by 1.40% trading at approximately $749.45 during pre-market sessions.

Frequently Asked Questions

What is Mounjaro?

Mounjaro is a GIP/GLP-1 dual receptor agonist developed by Eli Lilly for the treatment of obesity and weight management.

How does Mounjaro compare to Trulicity?

Mounjaro has shown superior outcomes regarding cardiovascular health and overall mortality in recent clinical trials compared to Trulicity.

What are the main findings from the SURPASS-CVOT trial?

The trial findings indicate that Mounjaro meets non-inferiority criteria while showing improvements in weight loss, A1C levels, and decreased cardiovascular mortality rates.

Are there any safety concerns regarding Mounjaro?

While some patients discontinued Mounjaro due to adverse events, the safety profile aligns with expectations based on prior GLP-1 agonist treatments.

What are the next steps for Eli Lilly with Mounjaro?

Eli Lilly aims to submit the trial data to global regulators to advance Mounjaro’s market position and expand its use in obesity treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 79

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 227

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 25

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 42

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 182

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from Key Shareholder Meetings: Tech and Industry Leaders

Updated Category News Views 229

Shareholder Meetings on the Horizon As we move into a new reporting season, the excitement surrounding the upcoming shareholder meetings is palpable. The recent financial results indicate a strong finish to the last quarter, with many companies showcasing impressive growth despite emerging macro challenges. The period after Q4 reporting sees a shift in focus toward the...

Continue Reading
Worldline Welcomes Pierre-Antoine Vacheron as CEO

Updated Category News Views 708

Worldline Welcomes Pierre-Antoine Vacheron as CEO Worldline, a leader in digital payments, has recently announced the appointment of Pierre-Antoine Vacheron as its new Chief Executive Officer. This strategic move, effective from March 1, signals a fresh start for the company as it continues to evolve within the rapidly changing payments industry. A Seasoned Professional...

Continue Reading
Autolus Therapeutics Set to Reveal Q2 2025 Financial Insights

Updated Category News Views 219

Autolus Therapeutics to Release Financial Results Soon Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering biopharmaceutical company, is gearing up to share its financial results for the second quarter of 2025. This announcement is set for shortly before the opening of U.S. markets. As a company focusing on next-generation programmed T cell therapies, the anticipation...

Continue Reading
Brightworks Dentistry Unites Practices Under One Brand

Updated Category News Views 28

New Brand Strategy in Atlanta's Dental Scene In an era where large dental chains seem to gobble up neighborhood practices like some corporate Pac-Man, Dr. Patrice Robbins takes a refreshing turn. Her brainchild, Brightworks Dentistry, is roping in all its Atlanta bases under one banner to keep that local warmth alive. By grouping Dunwoody, Buckhead, and Downtown Atlanta...

Continue Reading
AutoNation's Analyst Coverage Sparks Interest in Key Stocks

Updated Category News Views 48

Recent Insights from Analysts on AutoNation Wall Street analysts have recently published their latest evaluations of several well-known companies, presenting a blend of ratings and insights. In this article, we’ll explore the most recent coverage initiated by leading analysts, focusing specifically on AutoNation, Inc. and other notable companies. Understanding the...

Continue Reading